Monocloe Antibodies

3min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Monocle annabodies can be useful, but they are a bit finicky. You have to kind of pick and choose how and you use them. By the time you've been infected for a while, if your immune system's functioning, there's a good chance you've made this Annabody or something like it already. So that does look quite promising. And then you've got these trials, and some of the ones that we wrote about recently, where you're looking at people who have only recent become infected and are not very sick yet. They might see a benefit of using these sorts of monocle anna bodies.

In the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19.

But despite promising clinical trial results and several therapies having already been approved, antibody therapies have not yet played a large role in the fight against COVID-19. In this episode of Coronapod, we ask why.

News: COVID antibody treatments show promise for preventing severe disease

News: Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.